PubMed Health⌕ Search

PubMed · 14742885

Technical standardization for dual-energy x-ray absorptiometry.

Abstract

Clinical applications of dual-energy X-ray absorptiometry (DXA) should be updated periodically to address new technologies and inconsistencies in the use of existing technologies. The 2003 Position Development Conference of the International Society for Clinical Densitometry addressed issues regarding hip and forearm regions of interest (ROIs), vertebral fracture assessment (VFA), quality assurance (QA), precision, and cross-calibration. Data are insufficient to determine whether the mean T-score of both hips can be used for diagnosis. However, the mean bone mineral density of both hips can be used for monitoring. The 33% radius is the preferred forearm ROI for the diagnosis of osteoporosis. Data are insufficient to determine indications and clinical utility of VFA. Minimum standards for a QA program were established. Phantom scanning should be performed at least once per week. Precision assessment should use patients representative of a DXA center's patient population. If a center has more than one technologist, then the average precision may be used. Repeat precision assessment is necessary if a new DXA system is installed or a technologist's skills have changed. Knowledge of precision is critical to DXA interpretation, and approval from an institutional review board should not be required. Practical standardized procedures for cross-calibration of DXA systems should be developed.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Writing Group for the ISCD Position Development Conference. 2004. Technical standardization for dual-energy x-ray absorptiometry.. https://doi.org/10.1385/jcd%3A7%3A1%3A27

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

A repeated measures concordance correlation coefficient.

The concordance correlation coefficient is commonly used to assess agreement between two raters or two methods of measuring a response when the data are measured on a continuous scale. However, the situation may arise in which repeated measurements are taken for each rater or method, e.g. longitudinal studies in clinical trials or bioassay data with subsamples. This paper proposes a coefficient for measuring agreement between two raters or two methods of measuring a response in the presence of repeated measurements. We illustrate the methodology with examples comparing (1) 1-hr versus 2-hr blood draws for measuring cortisol in an asthma clinical trial and (2) two measurements of percentage body fat, from skinfold calipers and dual energy X-ray absorptiometry.

Absorptiometry, Photon↗

Crystallization and preliminary X-ray analysis of a domain in the Runx2 transcription factor that interacts with the 1alpha,25 dihydroxy vitamin D3 receptor.

The Runx2 transcription factor is a key regulator of osteoblast differentiation. In response to 1alpha,25 dihydroxy vitamin D3, Runx2 may interact with the 1alpha,25 dihydroxy vitamin D3 receptor (VDR) in the promoter of target genes, producing a synergic activation of their transcription. Previous studies have suggested that the motifs responsible for the VDR-Runx2 interaction are contained within the 230-361 domain of Runx2. In this work, we confirmed by GST-pull down that Runx2(I(209-361)) is sufficient to interact with the VDR. To obtain structural information, GST-Runx2(I(209-361)) protein was overexpressed in Escherichia coli, purified and crystallized using the hanging-drop vapor-diffusion method and polyethyleneglycol as a precipitant. The crystals were found to diffract to a maximum resolution of 2.7 A and a complete data set to a 3.3 A resolution was collected and analyzed. The crystals belong to the tetragonal system, with a space group P4 and unit-cell parameters of a = b = 90.8, and c = 57.2 A. The presence of a monomer of the recombinant GST-Runx2(I(209-361)) in the asymmetric unit gives a V(M) of 2.7 A(3) Da(-1) and a solvent content of 54.8%.

Absorptiometry, Photon↗

Quantifying the treatment effect explained by markers in the presence of measurement error.

Surrogate markers or intermediate markers are important in identifying subjects with high risk of a serious disease or for monitoring disease progression of a subject on treatment. Quantifying the proportion of treatment effect (PTE) explained by markers has been studied extensively. Due to reasons such as biological variation, limited machine precision, etc. markers are generally measured with error. The estimated PTE ignoring the measurement error could be biased, which may lead to incorrect conclusions. In this article, we adjust for the measurement error using regression calibration to construct a less biased estimator of excess relative odds, a quantity to measure the treatment effect explained by markers. The method is applied to data from a clinical study in osteoporosis.

Absorptiometry, Photon↗